Evidence map›Paper›PMID 36732282›Full record

ArticleImmunology2023

Mechanistic insight of interleukin-9 induced osteoclastogenesis.

Sushmita Chakraborty, Jakob Schneider, Dipendra Kumar Mitra, Katharina F Kubatzky

Open access · hybridAbstract read
In one paragraph

Article in Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sushmita ChakrabortyDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-0255-9532
Jakob SchneiderDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany.
Dipendra Kumar MitraDepartment of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India.
Katharina F KubatzkyDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-3739-9329
Heidelberg University · DEAll India Institute of Medical Sciences · IN

Funding

DBT-Wellcome Trust India Alliance IA/E/16/1/503016Wellcome Trust
6 · The paper itself

Abstract

Interleukin (IL)-9 is an emerging player in the pathogenesis of various chronic inflammatory diseases including bone disorders like rheumatoid arthritis (RA) and psoriatic arthritis. Recently, IL-9 was shown to enhance the osteoclast formation and their function in RA. However, the mechanisms by which IL-9 influences osteoclastogenesis are not known. Therefore, in this study we aimed to unravel the direct and indirect ways by which IL-9 can influence osteoclast formation. We used mouse bone marrow precursor cells for checking the effect of IL-9 on osteoclast differentiation and its function. Next, IL-9 induced signalling pathway were checked in the process of osteoclastogenesis. T cells play an important role in enhancing osteoclastogenesis in inflammatory conditions. We used splenic T cells to understand the impact of IL-9 on the functions of T effector (Teff) and regulatory T (Treg) cells. Furthermore, the effect of IL-9 mediated modulation of the T cell response on osteoclasts was checked using a coculture model of T cells with osteoclast precursors. We showed that IL-9 enhanced osteoclast formation and its function. We found that IL-9 activates STAT3, P38 MAPK, ERK1/2, NFκB and we hypothesize that it mediates the effect on osteoclastogenesis by accelerating mitochondrial biogenesis. Additionally, IL-9 was observed to facilitate the functions of pro-osteoclastogenic IL-17 producing T cells, but inhibits the function of anti-osteoclastogenic Treg cells. Our observations suggest that IL-9 can influence osteoclastogenesis directly by modulating the signalling cascade in the precursor cells; indirectly by enhancing IL-17 producing T cells and by reducing the functions of Treg cells.

Indexed as

Arthritis, RheumatoidOsteogenesisAnimalsCell DifferentiationCells, CulturedInterleukin-17Interleukin-9MiceOsteoclastsRANK LigandSignal TransductionInterleukin-17Interleukin-9RANK Ligandeffector T cellsinterleukin-9osteoclastregulatory T cellssignal transduction

Identifiers

PMID36732282
PMCPMC7615986
OpenAlexW4318938692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.